Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2019 07:15 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Second Quarter 2019 Financial Results

TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update. ...
August 05, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13

TEL AVIV, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
July 22, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit

TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
June 04, 2019 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today

TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International...
June 03, 2019 08:00 ET | Source: VBL Therapeutics

Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity

TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented...
June 03, 2019 08:00 ET | Source: VBL Therapeutics

VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer

VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03)CA-125 response (GCIG) was reported in 58% of evaluable...
May 23, 2019 09:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Presentations at the 2019 ASCO Annual Meeting and the BIO International Convention

TEL AVIV, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at...
May 15, 2019 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces First Quarter 2019 Financial Results

TEL AVIV, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update. “As...
May 06, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15

TEL AVIV, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
March 28, 2019 07:15 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update

Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM and colon cancerSigned...